Home Cart Sign in  
Chemical Structure| 1639792-20-3 Chemical Structure| 1639792-20-3

Structure of Saroglitazar magnesium
CAS No.: 1639792-20-3

Chemical Structure| 1639792-20-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with EC50 values of 0.65 pM and 3 nM for PPARα and PPARγ in HepG2 cells, respectively.

Synonyms: Saroglitazar magnesium

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Saroglitazar magnesium

CAS No. :1639792-20-3
Formula : C50H56MgN2O8S2
M.W : 901.42
SMILES Code : O=C1[O-][Mg+2]2(O([C@H]1CC3=CC=C(C=C3)OCCN4C(C5=CC=C(SC)C=C5)=CC=C4C)CC)[O-]C([C@H](CC6=CC=C(C=C6)OCCN7C(C8=CC=C(SC)C=C8)=CC=C7C)O2CC)=O
Synonyms :
Saroglitazar magnesium
MDL No. :MFCD29075338

Safety of Saroglitazar magnesium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 20 µM 48 hours To evaluate the effect of Saroglitazar on O/P-induced lipid accumulation. Results showed that Saroglitazar significantly reduced lipid accumulation, with a 50.5 ± 13.7% decrease in ORO-positive area. Ann Med. 2025 Dec;57(1):2497112
HepG2 and LX2 cells 10 µM 48 hours To evaluate the effect of Saroglitazar on palmitic acid-induced fibrosis marker gene expression. Results showed that Saroglitazar reduced the expression of TGF-β1, COL1A1, and α-SMA. Heliyon. 2023 Nov 4;9(11):e22051

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats High-fat diet-induced dyslipidemic rat model Oral ≥0.3 mg/kg Once daily for 4 weeks Evaluate the effect of Saroglitazar in combination with ACCi on liver and circulating TG Hepatol Commun. 2022 Sep;6(9):2298-2309.
Wistar rats Bleomycin-induced pulmonary fibrosis model Oral 3 mg/kg Daily for six weeks Saroglitazar significantly ameliorated bleomycin-induced pulmonary fibrosis by modulating oxidative stress, inflammatory and fibrotic markers, and enhancing the expression of autophagy-related genes. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):5953-5974
C57BL/6J mice High-fat diet-induced obesity model Oral 3 mg/kg Once daily for 12 weeks To evaluate the effect of Saroglitazar on high-fat diet-induced obesity, insulin resistance, and fatty liver. Results showed that Saroglitazar significantly reduced body weight, fasting blood glucose levels, improved glucose tolerance and insulin sensitivity, and reduced hepatic lipid accumulation. Heliyon. 2023 Nov 4;9(11):e22051
Human Type 2 diabetes patients Oral 4 mg daily Once daily for 14 weeks To evaluate the effects of Saroglitazar on glycaemic and lipid parameters in patients with Type 2 diabetes. Results showed significant improvements in fasting plasma glucose, post-prandial plasma glucose, glycosylated haemoglobin, total cholesterol, LDL cholesterol, triglyceride, non-HDL cholesterol, and the ratio of triglyceride to HDL cholesterol. Sci Rep. 2015 Jan 9;5:7706

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04446507 Renal Impairment PHASE1 COMPLETED 2024-05-28 Zydus US003, DeLand, Florida, ... More >>32720, United States|Zydus US001, San Antonio, Texas, 78215, United States Less <<
NCT04112446 Healthy PHASE1 COMPLETED 2019-10-29 Covance Clinical Research Unit... More >> Inc., Madison, Wisconsin, 53704, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.11mL

0.22mL

0.11mL

5.55mL

1.11mL

0.55mL

11.09mL

2.22mL

1.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories